Greenfire Bio
Greenfire Bio is a life science development and investment company based in Austin, Texas, founded in 2020. The firm focuses on building a diversified product pipeline by developing early-stage assets through proof of concept. Greenfire Bio engages in licensing, acquiring, partnering, or investing in unique pre-clinical or early clinical-stage programs. Its goal is to bridge the translational medicine gap and accelerate the development of innovative medical breakthroughs. The company is led by a team of experienced biopharma executives who aim to foster advancements in healthcare through strategic investments and collaborations.
1 past transactions
Pacylex
Series A in 2021
Pacylex Pharmaceuticals is focused on developing precision medicine solutions for various common cancers, including both blood and solid tumors. The company is advancing PCLX-001, a small molecule oral chemotherapeutic designed to induce selective lethality in cancer cells by targeting membrane-associated proteins involved in cancer signaling. This innovative approach aims to provide a potent alternative to traditional chemotherapies and immunotherapies. Additionally, Pacylex has created diagnostic technology to identify patients who are most likely to benefit from PCLX-001, thereby avoiding unnecessary treatments for those who would not respond. Founded in 2012 and based in Edmonton, Alberta, Canada, Pacylex Pharmaceuticals is pioneering first-in-kind therapies that may transform cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.